|
|
|
| Effect of Levosimendan combined with continuous static infusion of Fur- osemide on serum levels of soluble suppression of tumorigenicity-2, neuron- specific enolase in patients with acute decompensated heart failure |
| LI Yaping LI Haiyang ZHENG Gaomei |
Department of Cardiology, Fuyang People’s Hospital, Anhui Province, Fuyang 236000, China
|
|
|
|
Abstract Objective To investigate the effects of Levosimendan combined with continuous static infusion Furosemide on serum levels of soluble suppression of tumorigehicity 2 (sST-2) and neuron-specific enolase (NSE) in patients with acute decompensated heart failure (ADHF). Methods A total of 140 ADHF patients diagnosed and treated in Fuyang People’s Hospital of Anhui Province from January 2019 to October 2020 were selected and they were divided into Furosemide group (continuous static infusion Furosemide) and combination group (continuous static infusion Furosemide + Levosimendan) according to random number table method, with 70 cases in each group. Both groups were given conventional treatment and were treated for one week. The heart rate, left ventricular fractional shortening rate (LVFS), left ventricular ejection fraction (LVEF), sST-2, NSE, amino terminal brain natriuretic peptide precursor (NT-proBNP), right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), and mean pulmonary artery pressure (PAMP) were compared between the two groups before and after treatment. The incidence of adverse reaction was compared between the two groups. Results After treatment, the heart rate, sST-2, NSE, NT-proBNP, RAP, PCWP, and PAMP in both groups were lower than before treatment, LVFS and LVEF levels were higher than before treatment and the heart rate, sST-2, NSE, NT-proBNP, RAP, PCWP, and PAMP in combination group were lower than those in Furosemide group, LVFS and LVEF levels were higher than those in Furosemide group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Levosimendan combined with continuous static infusion Furosemide has significant therapeutic effect on ADHF patients, reducing the levels of sST-2 and NSE, improving hemodynamics and cardiac function of patients, which is worthy of clinical promotion.
|
|
|
|
|
|
[1] 潘辉军，汪春艳.急性失代偿性心力衰竭的治疗进展[J].医学综述，2020，26（17）：3461-3464，3470.
[2] 梁倩，刘静，柳红娟，等.急性失代偿性心力衰竭患者运动康复的研究进展[J].中华护理杂志，2022，57（5）：625-630.
[3] 郭卿，张晶，李东霞，等.托伐普坦对老年急性失代偿心力衰竭伴轻中度肾功能不全患者心肾功能的影响[J].中华老年心脑血管病杂志，2019，21（8）：793-796.
[4] 陈功，杨方，魏刚，等.重组人脑利钠肽联合左西孟旦治疗急性失代偿性心力衰竭合并肾功能不全的临床观察[J].中国药房，2020，31（21）：2639-2644.
[5] Ragab D，Taema KM，Farouk W，et al. Continuous infusion of furosemide versus intermittent boluses in acute decompensated heart failure：Effect on thoracic fluid content [J]. Egypt Heart J，2018，70（2）：65-70.
[6] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[7] Fisher JD. New York Heart Association Classification [J]. Arch Intern Med，1972，129（5）：836-842.
[8] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南[J].中华心血管病杂志，2010，38（3）：195-208.
[9] 李文安，刘凯，江帆，等.急性失代偿性心力衰竭患者血清碱性磷酸酶与肾功能恶化的相关性研究[J].中国全科医学，2018，21（7）：818-821.
[10] 杜亭亭，苗雨阳，刘欣，等.血浆脑钠肽对老年急性失代偿性心力衰竭患者再入院的预测价值[J].中华老年医学杂志，2018，37（11）：1204-1207.
[11] 徐志伟，成威，马聪，等.沙库巴曲缬沙坦治疗急性失代偿心力衰竭患者的效果[J].中国临床保健杂志，2020， 23（3）：403-407.
[12] Prins KW，Neill JM，Tyler JO，et al. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure： A Systematic Review and Meta-Analysis [J]. JACC Heart Fail，2015，3（8）：647-653.
[13] 王旭辉，周兴其. 托伐普坦对ADHF合并轻中度肾功能损伤患者利尿效果及电解质指标的影响[J].浙江创伤外科，2022，27（1）：125-127.
[14] 刘荣，于海波，许国卿，等.左西孟旦治疗急性失代偿性心力衰竭疗效分析[J].中国循环杂志，2015，30（z1）：57-58.
[15] 张建国，赵勇，马军力，等.左西孟旦治疗急性失代偿性心力衰竭的疗效及其安全性评估[J].心血管康复医学杂志，2022，31（5）：602-605.
[16] 荆峰.重组人脑利钠肽滴定给药方法治疗难治性急性失代偿心力衰竭的效果与安全性[J].中国当代医药，2021， 28（22）：24-27.
[17] 郭其，吕宝燕，王浩.高渗盐溶液联合呋塞米对急性失代偿性心力衰竭病人体重和血清肌酐水平的影响[J].中西医结合心脑血管病杂志，2019，17（18）：2860-2862.
[18] Singer Fisher E，Burns B. Acute Decompensated Heart Failure： New Strategies for Improving Outcomes[J]. Emerg Med Pract，2017，19（5）：1-24.
[19] 王丹，钟家蓉，张静.脑型利钠肽评估儿童扩张型心肌病急性失代偿性心力衰竭及心室重构的临床价值[J].儿科药学杂志，2018，24（8）：11-14.
[20] 杨晓慧，王力.左西孟旦对急性失代偿性心力衰竭患者血流动力学的影响[J].中国急救医学，2015，35（z2）：59-60.
[21] 张俊峰.参附注射液联合重组人脑利钠肽治疗急性失代偿性心力衰竭的临床疗效及安全性研究[J].海军医学杂志，2018，39（1）：38-43.
[22] 赵立杰，刘铭雅，朱伟，等.血清神经元特异性烯醇化酶对急性失代偿性心力衰竭预后的预测价值[J].临床心血管病杂志，2014，30（4）：298-301.
[23] 聂伟霞，高立，李涯，等.心脏磁共振DWI序列对肥厚型心肌病心肌纤维化诊断价值及与NT-ProBNP相关性分析[J].中国CT和MRI杂志，2023，21（1）：80-82.
[24] 毛威，陈晨.急性失代偿性心力衰竭时利尿剂抵抗的对策[J].心电与循环，2018，37（2）：86-89，95.
[25] 孙俊丽，郑有光，陈叶柔，等.左西孟旦治疗老年急性失代偿性心力衰竭的疗效[J].中国老年学杂志，2015，35（20）：5770-5771. |
|
|
|
